Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Eli Lilly stock dips on Novo Nordisk's rival drug data
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
BofA reiterates Eli Lilly buy rating, $997 target
BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...
MM&M5h
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
An Ozempic alternative shows promising weight loss results — and Novo Nordisk stock surges 12%
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Financial Buzz9h
Novo Nordisk Soars 12% With Ozempic Alternative
In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...
Alphabet Has an Nvidia-Like Business. It Could Be Worth Hundreds of Billions.
STOCKSTOWATCHTODAY BLOG Alphabet has an Nvidia -like business inside it. It could be the most valuable part of the internet search giant. Some investors might not know that Alphabet has an AI chip ...